Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies
The design of randomised controlled trials (RCTs) should incorporate characteristics (such as concealment of randomised allocation and blinding of participants and personnel) that avoid biases resulting from lack of comparability of the intervention and control groups. Empirical evidence suggests th...
Saved in:
Published in | Health technology assessment (Winchester, England) Vol. 16; no. 35; p. 1 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
NIHR Journals Library
01.09.2012
|
Subjects | |
Online Access | Get full text |
ISSN | 1366-5278 2046-4924 2046-4924 |
DOI | 10.3310/hta16350 |
Cover
Loading…
Abstract | The design of randomised controlled trials (RCTs) should incorporate characteristics (such as concealment of randomised allocation and blinding of participants and personnel) that avoid biases resulting from lack of comparability of the intervention and control groups. Empirical evidence suggests that the absence of such characteristics leads to biased intervention effect estimates, but the findings of different studies are not consistent.
To examine the influence of unclear or inadequate random sequence generation and allocation concealment, and unclear or absent double blinding, on intervention effect estimates and between-trial heterogeneity, and whether or not these influences vary with type of clinical area, intervention, comparison and outcome measure.
Data were combined from seven contributing meta-epidemiological studies (collections of meta-analyses in which trial characteristics are assessed and results recorded). The resulting database was used to identify and remove overlapping meta-analyses. Outcomes were coded such that odds ratios < 1 correspond to beneficial intervention effects. Outcome measures were classified as mortality, other objective or subjective. We examined agreement between assessments of trial characteristics in trials assessed in more than one contributing study. We used hierarchical Bayesian bias models to estimate the effect of trial characteristics on average bias [quantified as ratios of odds ratios (RORs) with 95% credible intervals (CrIs) comparing trials with and without a characteristic] and in increasing between-trial heterogeneity.
The analysis data set contained 1973 trials included in 234 meta-analyses. Median kappa statistics for agreement between assessments of trial characteristics were: sequence generation 0.60, allocation concealment 0.58 and blinding 0.87. Intervention effect estimates were exaggerated by an average 11% in trials with inadequate or unclear (compared with adequate) sequence generation (ROR 0.89, 95% CrI 0.82 to 0.96); between-trial heterogeneity was higher among such trials. Bias associated with inadequate or unclear sequence generation was greatest for subjective outcomes (ROR 0.83, 95% CrI 0.74 to 0.94) and the increase in heterogeneity was greatest for such outcomes [standard deviation (SD) 0.20, 95% CrI 0.03 to 0.32]. The effect of inadequate or unclear (compared with adequate) allocation concealment was greatest among meta-analyses with a subjectively assessed outcome intervention effect (ROR 0.85, 95% CrI 0.75 to 0.95), and the increase in between-trial heterogeneity was also greatest for such outcomes (SD 0.20, 95% CrI 0.02 to 0.33). Lack of, or unclear, double blinding (compared with double blinding) was associated with an average 13% exaggeration of intervention effects (ROR 0.87, 95% CrI 0.79 to 0.96), and between-trial heterogeneity was increased for such studies (SD 0.14, 95% CrI 0.02 to 0.30). Average bias (ROR 0.78, 95% CrI 0.65 to 0.92) and between-trial heterogeneity (SD 0.37, 95% CrI 0.19 to 0.53) were greatest for meta-analyses assessing subjective outcomes. Among meta-analyses with subjectively assessed outcomes, the effect of lack of blinding appeared greater than the effect of inadequate or unclear sequence generation or allocation concealment.
Bias associated with specific reported study design characteristics leads to exaggeration of beneficial intervention effect estimates and increases in between-trial heterogeneity. For each of the three characteristics assessed, these effects were greatest for subjectively assessed outcomes. Assessments of the risk of bias in RCTs should account for these findings. Further research is needed to understand the effects of attrition bias, as well as the relative importance of blinding of patients, care-givers and outcome assessors, and thus separate the effects of performance and detection bias.
National Institute for Health Research Health Technology Assessment programme. |
---|---|
AbstractList | The design of randomised controlled trials (RCTs) should incorporate characteristics (such as concealment of randomised allocation and blinding of participants and personnel) that avoid biases resulting from lack of comparability of the intervention and control groups. Empirical evidence suggests that the absence of such characteristics leads to biased intervention effect estimates, but the findings of different studies are not consistent.BACKGROUNDThe design of randomised controlled trials (RCTs) should incorporate characteristics (such as concealment of randomised allocation and blinding of participants and personnel) that avoid biases resulting from lack of comparability of the intervention and control groups. Empirical evidence suggests that the absence of such characteristics leads to biased intervention effect estimates, but the findings of different studies are not consistent.To examine the influence of unclear or inadequate random sequence generation and allocation concealment, and unclear or absent double blinding, on intervention effect estimates and between-trial heterogeneity, and whether or not these influences vary with type of clinical area, intervention, comparison and outcome measure.OBJECTIVESTo examine the influence of unclear or inadequate random sequence generation and allocation concealment, and unclear or absent double blinding, on intervention effect estimates and between-trial heterogeneity, and whether or not these influences vary with type of clinical area, intervention, comparison and outcome measure.Data were combined from seven contributing meta-epidemiological studies (collections of meta-analyses in which trial characteristics are assessed and results recorded). The resulting database was used to identify and remove overlapping meta-analyses. Outcomes were coded such that odds ratios < 1 correspond to beneficial intervention effects. Outcome measures were classified as mortality, other objective or subjective. We examined agreement between assessments of trial characteristics in trials assessed in more than one contributing study. We used hierarchical Bayesian bias models to estimate the effect of trial characteristics on average bias [quantified as ratios of odds ratios (RORs) with 95% credible intervals (CrIs) comparing trials with and without a characteristic] and in increasing between-trial heterogeneity.DATA SOURCES AND METHODSData were combined from seven contributing meta-epidemiological studies (collections of meta-analyses in which trial characteristics are assessed and results recorded). The resulting database was used to identify and remove overlapping meta-analyses. Outcomes were coded such that odds ratios < 1 correspond to beneficial intervention effects. Outcome measures were classified as mortality, other objective or subjective. We examined agreement between assessments of trial characteristics in trials assessed in more than one contributing study. We used hierarchical Bayesian bias models to estimate the effect of trial characteristics on average bias [quantified as ratios of odds ratios (RORs) with 95% credible intervals (CrIs) comparing trials with and without a characteristic] and in increasing between-trial heterogeneity.The analysis data set contained 1973 trials included in 234 meta-analyses. Median kappa statistics for agreement between assessments of trial characteristics were: sequence generation 0.60, allocation concealment 0.58 and blinding 0.87. Intervention effect estimates were exaggerated by an average 11% in trials with inadequate or unclear (compared with adequate) sequence generation (ROR 0.89, 95% CrI 0.82 to 0.96); between-trial heterogeneity was higher among such trials. Bias associated with inadequate or unclear sequence generation was greatest for subjective outcomes (ROR 0.83, 95% CrI 0.74 to 0.94) and the increase in heterogeneity was greatest for such outcomes [standard deviation (SD) 0.20, 95% CrI 0.03 to 0.32]. The effect of inadequate or unclear (compared with adequate) allocation concealment was greatest among meta-analyses with a subjectively assessed outcome intervention effect (ROR 0.85, 95% CrI 0.75 to 0.95), and the increase in between-trial heterogeneity was also greatest for such outcomes (SD 0.20, 95% CrI 0.02 to 0.33). Lack of, or unclear, double blinding (compared with double blinding) was associated with an average 13% exaggeration of intervention effects (ROR 0.87, 95% CrI 0.79 to 0.96), and between-trial heterogeneity was increased for such studies (SD 0.14, 95% CrI 0.02 to 0.30). Average bias (ROR 0.78, 95% CrI 0.65 to 0.92) and between-trial heterogeneity (SD 0.37, 95% CrI 0.19 to 0.53) were greatest for meta-analyses assessing subjective outcomes. Among meta-analyses with subjectively assessed outcomes, the effect of lack of blinding appeared greater than the effect of inadequate or unclear sequence generation or allocation concealment.RESULTSThe analysis data set contained 1973 trials included in 234 meta-analyses. Median kappa statistics for agreement between assessments of trial characteristics were: sequence generation 0.60, allocation concealment 0.58 and blinding 0.87. Intervention effect estimates were exaggerated by an average 11% in trials with inadequate or unclear (compared with adequate) sequence generation (ROR 0.89, 95% CrI 0.82 to 0.96); between-trial heterogeneity was higher among such trials. Bias associated with inadequate or unclear sequence generation was greatest for subjective outcomes (ROR 0.83, 95% CrI 0.74 to 0.94) and the increase in heterogeneity was greatest for such outcomes [standard deviation (SD) 0.20, 95% CrI 0.03 to 0.32]. The effect of inadequate or unclear (compared with adequate) allocation concealment was greatest among meta-analyses with a subjectively assessed outcome intervention effect (ROR 0.85, 95% CrI 0.75 to 0.95), and the increase in between-trial heterogeneity was also greatest for such outcomes (SD 0.20, 95% CrI 0.02 to 0.33). Lack of, or unclear, double blinding (compared with double blinding) was associated with an average 13% exaggeration of intervention effects (ROR 0.87, 95% CrI 0.79 to 0.96), and between-trial heterogeneity was increased for such studies (SD 0.14, 95% CrI 0.02 to 0.30). Average bias (ROR 0.78, 95% CrI 0.65 to 0.92) and between-trial heterogeneity (SD 0.37, 95% CrI 0.19 to 0.53) were greatest for meta-analyses assessing subjective outcomes. Among meta-analyses with subjectively assessed outcomes, the effect of lack of blinding appeared greater than the effect of inadequate or unclear sequence generation or allocation concealment.Bias associated with specific reported study design characteristics leads to exaggeration of beneficial intervention effect estimates and increases in between-trial heterogeneity. For each of the three characteristics assessed, these effects were greatest for subjectively assessed outcomes. Assessments of the risk of bias in RCTs should account for these findings. Further research is needed to understand the effects of attrition bias, as well as the relative importance of blinding of patients, care-givers and outcome assessors, and thus separate the effects of performance and detection bias.CONCLUSIONSBias associated with specific reported study design characteristics leads to exaggeration of beneficial intervention effect estimates and increases in between-trial heterogeneity. For each of the three characteristics assessed, these effects were greatest for subjectively assessed outcomes. Assessments of the risk of bias in RCTs should account for these findings. Further research is needed to understand the effects of attrition bias, as well as the relative importance of blinding of patients, care-givers and outcome assessors, and thus separate the effects of performance and detection bias.National Institute for Health Research Health Technology Assessment programme.FUNDINGNational Institute for Health Research Health Technology Assessment programme. The design of randomised controlled trials (RCTs) should incorporate characteristics (such as concealment of randomised allocation and blinding of participants and personnel) that avoid biases resulting from lack of comparability of the intervention and control groups. Empirical evidence suggests that the absence of such characteristics leads to biased intervention effect estimates, but the findings of different studies are not consistent. To examine the influence of unclear or inadequate random sequence generation and allocation concealment, and unclear or absent double blinding, on intervention effect estimates and between-trial heterogeneity, and whether or not these influences vary with type of clinical area, intervention, comparison and outcome measure. Data were combined from seven contributing meta-epidemiological studies (collections of meta-analyses in which trial characteristics are assessed and results recorded). The resulting database was used to identify and remove overlapping meta-analyses. Outcomes were coded such that odds ratios < 1 correspond to beneficial intervention effects. Outcome measures were classified as mortality, other objective or subjective. We examined agreement between assessments of trial characteristics in trials assessed in more than one contributing study. We used hierarchical Bayesian bias models to estimate the effect of trial characteristics on average bias [quantified as ratios of odds ratios (RORs) with 95% credible intervals (CrIs) comparing trials with and without a characteristic] and in increasing between-trial heterogeneity. The analysis data set contained 1973 trials included in 234 meta-analyses. Median kappa statistics for agreement between assessments of trial characteristics were: sequence generation 0.60, allocation concealment 0.58 and blinding 0.87. Intervention effect estimates were exaggerated by an average 11% in trials with inadequate or unclear (compared with adequate) sequence generation (ROR 0.89, 95% CrI 0.82 to 0.96); between-trial heterogeneity was higher among such trials. Bias associated with inadequate or unclear sequence generation was greatest for subjective outcomes (ROR 0.83, 95% CrI 0.74 to 0.94) and the increase in heterogeneity was greatest for such outcomes [standard deviation (SD) 0.20, 95% CrI 0.03 to 0.32]. The effect of inadequate or unclear (compared with adequate) allocation concealment was greatest among meta-analyses with a subjectively assessed outcome intervention effect (ROR 0.85, 95% CrI 0.75 to 0.95), and the increase in between-trial heterogeneity was also greatest for such outcomes (SD 0.20, 95% CrI 0.02 to 0.33). Lack of, or unclear, double blinding (compared with double blinding) was associated with an average 13% exaggeration of intervention effects (ROR 0.87, 95% CrI 0.79 to 0.96), and between-trial heterogeneity was increased for such studies (SD 0.14, 95% CrI 0.02 to 0.30). Average bias (ROR 0.78, 95% CrI 0.65 to 0.92) and between-trial heterogeneity (SD 0.37, 95% CrI 0.19 to 0.53) were greatest for meta-analyses assessing subjective outcomes. Among meta-analyses with subjectively assessed outcomes, the effect of lack of blinding appeared greater than the effect of inadequate or unclear sequence generation or allocation concealment. Bias associated with specific reported study design characteristics leads to exaggeration of beneficial intervention effect estimates and increases in between-trial heterogeneity. For each of the three characteristics assessed, these effects were greatest for subjectively assessed outcomes. Assessments of the risk of bias in RCTs should account for these findings. Further research is needed to understand the effects of attrition bias, as well as the relative importance of blinding of patients, care-givers and outcome assessors, and thus separate the effects of performance and detection bias. National Institute for Health Research Health Technology Assessment programme. Background: The design of randomised controlled trials (RCTs) should incorporate characteristics (such as concealment of randomised allocation and blinding of participants and personnel) that avoid biases resulting from lack of comparability of the intervention and control groups. Empirical evidence suggests that the absence of such characteristics leads to biased intervention effect estimates, but the findings of different studies are not consistent. Objectives: To examine the influence of unclear or inadequate random sequence generation and allocation concealment, and unclear or absent double blinding, on intervention effect estimates and between-trial heterogeneity, and whether or not these influences vary with type of clinical area, intervention, comparison and outcome measure. Data sources and methods: Data were combined from seven contributing meta-epidemiological studies (collections of meta-analyses in which trial characteristics are assessed and results recorded). The resulting database was used to identify and remove overlapping meta-analyses. Outcomes were coded such that odds ratios < 1 correspond to beneficial intervention effects. Outcome measures were classified as mortality, other objective or subjective. We examined agreement between assessments of trial characteristics in trials assessed in more than one contributing study. We used hierarchical Bayesian bias models to estimate the effect of trial characteristics on average bias [quantified as ratios of odds ratios (RORs) with 95% credible intervals (CrIs) comparing trials with and without a characteristic] and in increasing between-trial heterogeneity. Results: The analysis data set contained 1973 trials included in 234 meta-analyses. Median kappa statistics for agreement between assessments of trial characteristics were: sequence generation 0.60, allocation concealment 0.58 and blinding 0.87. Intervention effect estimates were exaggerated by an average 11% in trials with inadequate or unclear (compared with adequate) sequence generation (ROR 0.89, 95% CrI 0.82 to 0.96); between-trial heterogeneity was higher among such trials. Bias associated with inadequate or unclear sequence generation was greatest for subjective outcomes (ROR 0.83, 95% CrI 0.74 to 0.94) and the increase in heterogeneity was greatest for such outcomes [standard deviation (SD) 0.20, 95% CrI 0.03 to 0.32]. The effect of inadequate or unclear (compared with adequate) allocation concealment was greatest among meta-analyses with a subjectively assessed outcome intervention effect (ROR 0.85, 95% CrI 0.75 to 0.95), and the increase in between-trial heterogeneity was also greatest for such outcomes (SD 0.20, 95% CrI 0.02 to 0.33). Lack of, or unclear, double blinding (compared with double blinding) was associated with an average 13% exaggeration of intervention effects (ROR 0.87, 95% CrI 0.79 to 0.96), and between-trial heterogeneity was increased for such studies (SD 0.14, 95% CrI 0.02 to 0.30). Average bias (ROR 0.78, 95% CrI 0.65 to 0.92) and between-trial heterogeneity (SD 0.37, 95% CrI 0.19 to 0.53) were greatest for meta-analyses assessing subjective outcomes. Among meta-analyses with subjectively assessed outcomes, the effect of lack of blinding appeared greater than the effect of inadequate or unclear sequence generation or allocation concealment. Conclusions: Bias associated with specific reported study design characteristics leads to exaggeration of beneficial intervention effect estimates and increases in between-trial heterogeneity. For each of the three characteristics assessed, these effects were greatest for subjectively assessed outcomes. Assessments of the risk of bias in RCTs should account for these findings. Further research is needed to understand the effects of attrition bias, as well as the relative importance of blinding of patients, care-givers and outcome assessors, and thus separate the effects of performance and detection bias. Funding: National Institute for Health Research Health Technology Assessment programme. |
Author | Sterne, JAC Gluud, C Schulz, KF Jűni, P Jones, HE Altman, DG Moher, D Pildal, J Beynon, R Harris, RJ Balk, EM Ioannidis, JPA Als-Nielsen, B Wood, L Deeks, JJ Gluud, LL Savović, J Welton, N |
Author_xml | – sequence: 1 givenname: J surname: Savović fullname: Savović, J organization: School of Social and Community Medicine, University of Bristol, Bristol, UK – sequence: 2 givenname: HE surname: Jones fullname: Jones, HE – sequence: 3 givenname: DG surname: Altman fullname: Altman, DG – sequence: 4 givenname: RJ surname: Harris fullname: Harris, RJ – sequence: 5 givenname: P surname: Jűni fullname: Jűni, P – sequence: 6 givenname: J surname: Pildal fullname: Pildal, J – sequence: 7 givenname: B surname: Als-Nielsen fullname: Als-Nielsen, B – sequence: 8 givenname: EM surname: Balk fullname: Balk, EM – sequence: 9 givenname: C surname: Gluud fullname: Gluud, C – sequence: 10 givenname: LL surname: Gluud fullname: Gluud, LL – sequence: 11 givenname: JPA surname: Ioannidis fullname: Ioannidis, JPA – sequence: 12 givenname: KF surname: Schulz fullname: Schulz, KF – sequence: 13 givenname: R surname: Beynon fullname: Beynon, R – sequence: 14 givenname: N surname: Welton fullname: Welton, N – sequence: 15 givenname: L surname: Wood fullname: Wood, L – sequence: 16 givenname: D surname: Moher fullname: Moher, D – sequence: 17 givenname: JJ surname: Deeks fullname: Deeks, JJ – sequence: 18 givenname: JAC surname: Sterne fullname: Sterne, JAC |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22989478$$D View this record in MEDLINE/PubMed |
BookMark | eNplUsluFDEQtVAQWUDiC1AfuXTw1m43NxSxjBSJC5xb1XZ54shtD7YHaf4on4knGxKc7Hp-9ar8qs7JSUwRCXnL6KUQjH64qcCUGOgLcsapVL2cuDwhZ0wo1Q981KfkvJRbSiVTA3tFTjmf9CRHfUbuNtGFPUaDXXJdxl3KFW1X6t4eOovFb2NnbiCDqZh9qd6ULsXOxxb-xlh9C9A5NLXD9rpCxdK5nNYuQ7Rp9aWpmRRrTiG0a80eQvnYoHXxsQEQIRyKL8fyK1bocectrj6FtPUGwn0rHstr8tK1THzzeF6Qn18-_7j61l9__7q5-nTdG6FF7aUdlWpewKLRKjmNODGnF80mOhk1wLSoxdlJgwYQTlNnuGOCDuOgpFCOiwuyedC1CW7nXW5fyoc5gZ_vgZS3M-RmQ8CZWsOtgwWbiBwlhRYI5hbrpDALX5rW-wetXU6_9s2fuflhMASImPZlZm0ggg-aj4367pG6X1a0z4WfJvVXy-RUSkb3TGF0Pi7B_LQEjXr5D9X4CsdR1Qw-_J_wB6mguUE |
CitedBy_id | crossref_primary_10_1002_14651858_CD011736_pub2 crossref_primary_10_2522_ptj_20140480 crossref_primary_10_1002_14651858_CD005440_pub3 crossref_primary_10_1002_14651858_CD014216 crossref_primary_10_1080_01443615_2020_1820461 crossref_primary_10_1002_14651858_CD006935_pub2 crossref_primary_10_1002_14651858_CD013121 crossref_primary_10_1002_14651858_CD013120 crossref_primary_10_1002_14651858_CD013361 crossref_primary_10_2341_17_060_L crossref_primary_10_1002_14651858_CD013125 crossref_primary_10_1002_14651858_CD013123 crossref_primary_10_1002_14651858_CD013122 crossref_primary_10_1002_14651858_CD010488_pub2 crossref_primary_10_1371_journal_pmed_1004215 crossref_primary_10_1002_14651858_CD004260_pub3 crossref_primary_10_1111_jep_13019 crossref_primary_10_1371_journal_pone_0128061 crossref_primary_10_20960_angiologia_00700 crossref_primary_10_1097_PR9_0000000000000854 crossref_primary_10_1002_14651858_CD011640_pub2 crossref_primary_10_2217_cer_2019_0201 crossref_primary_10_1002_14651858_MR000050_pub2 crossref_primary_10_1136_bmj_l4697 crossref_primary_10_1177_1941738121998712 crossref_primary_10_1002_14651858_CD012168 crossref_primary_10_1002_jbmr_2036 crossref_primary_10_1002_14651858_CD003046_pub3 crossref_primary_10_1111_cid_12114 crossref_primary_10_1111_bcp_13350 crossref_primary_10_1002_14651858_CD013107 crossref_primary_10_12968_jowc_2020_29_2_79 crossref_primary_10_1002_14651858_CD009060_pub2 crossref_primary_10_1002_14651858_CD012138 crossref_primary_10_1002_14651858_CD013106 crossref_primary_10_1002_14651858_CD011647_pub2 crossref_primary_10_1002_14651858_CD013103_pub2 crossref_primary_10_1002_14651858_CD009918_pub2 crossref_primary_10_1002_14651858_CD003328_pub3 crossref_primary_10_1002_14651858_CD013103 crossref_primary_10_1016_j_mayocpiqo_2023_04_010 crossref_primary_10_1002_14651858_CD012496 crossref_primary_10_1002_14651858_CD012495 crossref_primary_10_1002_14651858_CD007196_pub3 crossref_primary_10_1002_14651858_CD013204_pub2 crossref_primary_10_1002_14651858_CD013120_pub2 crossref_primary_10_1016_j_jclinepi_2024_111644 crossref_primary_10_1038_s41416_020_0761_6 crossref_primary_10_1002_14651858_CD013532_pub2 crossref_primary_10_1002_14651858_CD006745_pub3 crossref_primary_10_1002_14651858_CD011644_pub3 crossref_primary_10_1002_14651858_CD011644_pub2 crossref_primary_10_1002_14651858_CD013471 crossref_primary_10_1002_14651858_CD008545_pub2 crossref_primary_10_1111_nmo_12289 crossref_primary_10_1002_14651858_CD009059_pub2 crossref_primary_10_1002_14651858_CD010872_pub2 crossref_primary_10_1002_14651858_CD005642_pub3 crossref_primary_10_1186_s13643_017_0470_2 crossref_primary_10_1016_j_cct_2015_07_019 crossref_primary_10_1002_14651858_CD010479_pub2 crossref_primary_10_1002_14651858_CD012359 crossref_primary_10_1002_14651858_CD012608_pub2 crossref_primary_10_1002_14651858_CD012358 crossref_primary_10_1002_14651858_CD012608_pub3 crossref_primary_10_1002_14651858_CD013204 crossref_primary_10_1080_09638237_2016_1244716 crossref_primary_10_1002_14651858_CD011026 crossref_primary_10_1002_14651858_CD013203 crossref_primary_10_1002_14651858_CD007470_pub3 crossref_primary_10_1080_08870446_2014_953531 crossref_primary_10_1289_ehp_1510532 crossref_primary_10_1002_ebch_1985 crossref_primary_10_1002_14651858_CD013107_pub2 crossref_primary_10_4178_epih_e2014019 crossref_primary_10_1186_s13643_019_0957_0 crossref_primary_10_1016_j_jclinepi_2015_03_008 crossref_primary_10_1002_14651858_CD011039 crossref_primary_10_1002_14651858_CD011037 crossref_primary_10_1002_14651858_CD013214 crossref_primary_10_1002_14651858_CD009058_pub2 crossref_primary_10_1002_14651858_CD009058_pub3 crossref_primary_10_1002_14651858_CD010164_pub2 crossref_primary_10_1186_s13643_019_1233_z crossref_primary_10_1002_14651858_CD012123 crossref_primary_10_1002_14651858_CD012244 crossref_primary_10_1016_j_jclinepi_2020_06_025 crossref_primary_10_1002_14651858_CD011659_pub2 crossref_primary_10_1002_14651858_CD013156_pub2 crossref_primary_10_1080_21641846_2020_1848262 crossref_primary_10_1002_14651858_CD011711_pub2 crossref_primary_10_1016_S1877_1203_21_00097_5 crossref_primary_10_1371_journal_pone_0141588 crossref_primary_10_1002_14651858_CD014637 crossref_primary_10_1002_14651858_CD013545 crossref_primary_10_1177_1457496918812208 crossref_primary_10_1002_14651858_CD011639_pub2 crossref_primary_10_1002_14651858_CD007049_pub2 crossref_primary_10_1002_14651858_CD014636 crossref_primary_10_1111_add_15056 crossref_primary_10_1016_j_joen_2019_10_016 crossref_primary_10_1002_14651858_CD013301 crossref_primary_10_1177_13591053211059391 crossref_primary_10_1002_14651858_CD011002 crossref_primary_10_1002_14651858_CD012694 crossref_primary_10_1002_14651858_CD011451_pub2 crossref_primary_10_1016_j_ijnurstu_2020_103846 crossref_primary_10_1016_j_jclinepi_2016_04_005 crossref_primary_10_1097_AJP_0000000000000265 crossref_primary_10_1002_epi4_12644 crossref_primary_10_1002_jrsm_1700 crossref_primary_10_1002_14651858_CD007109_pub2 crossref_primary_10_1002_14651858_CD011510_pub2 crossref_primary_10_1002_14651858_CD013090_pub2 crossref_primary_10_1002_14651858_CD014764 crossref_primary_10_1186_s13643_021_01692_8 crossref_primary_10_3389_fphar_2024_1288479 crossref_primary_10_1002_14651858_CD013431 crossref_primary_10_1002_14651858_CD010253_pub2 crossref_primary_10_1002_14651858_CD011564_pub3 crossref_primary_10_1136_ard_2024_226129 crossref_primary_10_1002_14651858_CD011564_pub2 crossref_primary_10_1002_14651858_CD013114_pub2 crossref_primary_10_1002_14651858_CD014869_pub2 crossref_primary_10_1002_14651858_CD013646 crossref_primary_10_1016_j_watres_2014_11_033 crossref_primary_10_1002_14651858_CD006004_pub4 crossref_primary_10_1007_s10151_017_1585_0 crossref_primary_10_1371_journal_pone_0088008 crossref_primary_10_1002_14651858_CD005441_pub3 crossref_primary_10_1002_14651858_CD012481_pub2 crossref_primary_10_1186_2046_4053_3_14 crossref_primary_10_1038_s41598_022_24447_4 crossref_primary_10_1186_s13063_015_0975_8 crossref_primary_10_1002_14651858_CD011585_pub2 crossref_primary_10_1007_s40279_024_02158_2 crossref_primary_10_1016_j_jclinepi_2023_11_001 crossref_primary_10_1002_14651858_CD010507_pub2 crossref_primary_10_1002_14651858_CD014869 crossref_primary_10_1002_14651858_CD013532 crossref_primary_10_1002_14651858_CD013653 crossref_primary_10_1002_14651858_CD011233 crossref_primary_10_1186_2046_4053_3_23 crossref_primary_10_1002_14651858_CD006798_pub4 crossref_primary_10_1002_14651858_CD013089_pub2 crossref_primary_10_1016_j_jclinepi_2018_04_017 crossref_primary_10_1002_14651858_CD011506_pub2 crossref_primary_10_1016_j_jclinepi_2018_04_016 crossref_primary_10_1093_aje_kwx344 crossref_primary_10_1002_jrsm_1614 crossref_primary_10_1002_14651858_CD012897 crossref_primary_10_1002_14651858_CD013502 crossref_primary_10_1002_14651858_CD011564 crossref_primary_10_1002_14651858_CD012411 crossref_primary_10_1002_14651858_CD013500 crossref_primary_10_1002_14651858_CD013749 crossref_primary_10_1111_ijn_12948 crossref_primary_10_1002_14651858_CD011568 crossref_primary_10_1186_s13643_018_0838_y crossref_primary_10_1002_14651858_CD011561 crossref_primary_10_1111_add_14969 crossref_primary_10_1002_14651858_CD013157_pub2 crossref_primary_10_1016_j_ctrv_2017_03_012 crossref_primary_10_1111_aas_13513 crossref_primary_10_1002_jrsm_1620 crossref_primary_10_1002_14651858_CD009497_pub3 crossref_primary_10_1002_14651858_CD009497_pub2 crossref_primary_10_1001_jamainternmed_2019_1501 crossref_primary_10_1002_14651858_CD013997 crossref_primary_10_1002_14651858_CD011313_pub2 crossref_primary_10_1002_14651858_CD011313_pub3 crossref_primary_10_1002_14651858_CD011660_pub2 crossref_primary_10_1002_14651858_CD001277_pub3 crossref_primary_10_1002_14651858_CD011573 crossref_primary_10_1002_14651858_CD010683_pub3 crossref_primary_10_1002_14651858_CD011451 crossref_primary_10_1002_14651858_CD011017_pub2 crossref_primary_10_1002_14651858_CD013106_pub2 crossref_primary_10_1186_s13049_025_01334_1 crossref_primary_10_1002_14651858_CD011645_pub2 crossref_primary_10_1007_s10151_017_1583_2 crossref_primary_10_1002_14651858_CD012758 crossref_primary_10_1002_14651858_CD012757 crossref_primary_10_1016_j_msksp_2021_102426 crossref_primary_10_1053_j_ajkd_2019_10_004 crossref_primary_10_1002_14651858_CD006574_pub4 crossref_primary_10_1002_14651858_CD012069_pub2 crossref_primary_10_1016_j_jclinepi_2017_11_026 crossref_primary_10_1002_14651858_CD010587 crossref_primary_10_1002_14651858_CD010588 crossref_primary_10_1002_14651858_CD012400 crossref_primary_10_1002_14651858_CD013731 crossref_primary_10_1016_j_bja_2024_05_033 crossref_primary_10_3724_zdxbyxb_2023_0072 crossref_primary_10_1002_14651858_CD014944 crossref_primary_10_1002_14651858_CD007337_pub4 crossref_primary_10_1002_14651858_CD007337_pub3 crossref_primary_10_1002_14651858_CD007606_pub4 crossref_primary_10_1002_14651858_CD012956_pub2 crossref_primary_10_1002_14651858_CD007606_pub3 crossref_primary_10_1016_j_ejim_2016_03_020 crossref_primary_10_1016_j_jclinepi_2017_11_025 crossref_primary_10_1155_2020_4308380 crossref_primary_10_1016_j_maturitas_2015_11_013 crossref_primary_10_1002_14651858_CD011643 crossref_primary_10_1002_14651858_CD011641 crossref_primary_10_1080_17434440_2022_2039623 crossref_primary_10_1002_14651858_CD011769 crossref_primary_10_1002_14651858_CD012971 crossref_primary_10_1002_14651858_CD004547_pub2 crossref_primary_10_1016_j_imr_2024_101043 crossref_primary_10_1002_jrsm_1543 crossref_primary_10_1016_j_jid_2018_11_019 crossref_primary_10_1002_14651858_CD006006_pub3 crossref_primary_10_1136_openhrt_2020_001288 crossref_primary_10_1186_s12874_019_0804_y crossref_primary_10_1002_14651858_CD008716_pub3 crossref_primary_10_1002_14651858_CD012358_pub2 crossref_primary_10_1002_14651858_CD011659 crossref_primary_10_1002_14651858_CD011803_pub2 crossref_primary_10_1186_s13063_018_3136_z crossref_primary_10_1016_j_jclinepi_2016_02_001 crossref_primary_10_1016_j_nbd_2013_10_014 crossref_primary_10_1111_aas_14316 crossref_primary_10_1186_s12888_019_2048_0 crossref_primary_10_1002_14651858_CD005640_pub3 crossref_primary_10_1111_opo_12394 crossref_primary_10_1002_14651858_CD011598_pub2 crossref_primary_10_1080_17512433_2021_1933434 crossref_primary_10_1002_14651858_CD011746 crossref_primary_10_1002_14651858_CD012956 crossref_primary_10_1002_14651858_CD010897 crossref_primary_10_1002_14651858_CD012955 crossref_primary_10_1111_phn_12240 crossref_primary_10_3389_fvets_2023_1137781 crossref_primary_10_1002_14651858_CD011981 crossref_primary_10_1016_j_jelekin_2022_102657 crossref_primary_10_3390_w10060744 crossref_primary_10_1002_14651858_CD001511_pub2 crossref_primary_10_1002_14651858_CD001511_pub3 crossref_primary_10_1002_14651858_CD001511_pub4 crossref_primary_10_47924_neurotarget2022124 crossref_primary_10_1002_14651858_CD008143_pub4 crossref_primary_10_1002_14651858_CD004792_pub5 crossref_primary_10_1002_14651858_CD008261_pub2 crossref_primary_10_1371_journal_pone_0159267 crossref_primary_10_1002_14651858_CD012608 crossref_primary_10_1002_14651858_CD002798_pub3 crossref_primary_10_1002_14651858_CD002798_pub4 crossref_primary_10_1089_tmj_2024_0050 crossref_primary_10_1371_journal_pone_0194027 crossref_primary_10_1002_14651858_CD010545 crossref_primary_10_1002_14651858_CD010546 crossref_primary_10_1002_14651858_CD009498_pub3 crossref_primary_10_1002_14651858_CD009498_pub4 crossref_primary_10_1002_14651858_CD006007_pub4 crossref_primary_10_1002_14651858_CD011717_pub2 crossref_primary_10_1002_14651858_CD008623_pub2 crossref_primary_10_1002_14651858_CD011650_pub2 crossref_primary_10_1002_14651858_CD011727 crossref_primary_10_1002_cl2_1027 crossref_primary_10_54846_jshap_1313 crossref_primary_10_1002_14651858_CD010872 crossref_primary_10_1002_14651858_CD012814 crossref_primary_10_1177_0193841X221116721 crossref_primary_10_1016_j_apmr_2014_10_026 crossref_primary_10_1002_14651858_CD012123_pub2 crossref_primary_10_1111_tmi_12330 crossref_primary_10_1002_14651858_CD010340_pub2 crossref_primary_10_1002_hec_3474 crossref_primary_10_1097_MCC_0000000000000618 crossref_primary_10_1016_j_jclinepi_2020_03_024 crossref_primary_10_1111_aas_13358 crossref_primary_10_1002_14651858_CD010163_pub3 crossref_primary_10_1002_14651858_CD011973 crossref_primary_10_1002_14651858_CD010163_pub2 crossref_primary_10_1186_s12891_016_1271_9 crossref_primary_10_1002_14651858_CD010478_pub2 crossref_primary_10_1002_14651858_CD010125_pub2 crossref_primary_10_1186_2046_4053_3_81 crossref_primary_10_1016_j_clnesp_2019_05_002 crossref_primary_10_3310_pgfar04070 crossref_primary_10_1186_2046_4053_3_89 crossref_primary_10_1002_14651858_CD011949 crossref_primary_10_1186_s12916_022_02540_9 crossref_primary_10_1186_s13643_023_02307_0 crossref_primary_10_1002_14651858_CD013122_pub2 crossref_primary_10_1002_14651858_CD012955_pub2 crossref_primary_10_1111_jcpe_12394 crossref_primary_10_1002_14651858_CD012673_pub2 crossref_primary_10_1186_s13643_023_02308_z crossref_primary_10_1016_j_jad_2015_03_042 crossref_primary_10_1002_14651858_CD012143_pub3 crossref_primary_10_1002_14651858_CD012143_pub2 crossref_primary_10_1002_14651858_CD006660_pub3 crossref_primary_10_1542_peds_2018_3390 crossref_primary_10_1111_aas_13313 crossref_primary_10_1002_14651858_CD010252_pub2 crossref_primary_10_1002_14651858_CD010507 crossref_primary_10_1002_14651858_CD011717 crossref_primary_10_1002_14651858_CD011746_pub2 crossref_primary_10_1002_14651858_CD006930_pub3 crossref_primary_10_1002_14651858_CD010505 crossref_primary_10_1002_14651858_CD012805 crossref_primary_10_1002_14651858_CD010506 crossref_primary_10_1016_j_burns_2017_08_009 crossref_primary_10_1002_14651858_CD010504 crossref_primary_10_1007_s00423_013_1136_8 crossref_primary_10_21307_sjcapp_2018_003 crossref_primary_10_1016_j_jclinepi_2014_06_001 crossref_primary_10_1111_aos_15160 crossref_primary_10_1177_15245004241230310 crossref_primary_10_1002_14651858_CD013155_pub2 crossref_primary_10_1002_14651858_CD011314_pub2 crossref_primary_10_1007_s00134_013_2947_3 crossref_primary_10_1002_14651858_CD009004_pub2 crossref_primary_10_1002_14651858_CD010838 crossref_primary_10_1179_1465313314Y_0000000110 crossref_primary_10_1002_14651858_CD011803 crossref_primary_10_1002_14651858_CD007088_pub2 crossref_primary_10_1111_aas_13329 crossref_primary_10_1002_14651858_CD012345_pub3 crossref_primary_10_1002_14651858_CD012345_pub2 crossref_primary_10_1002_14651858_CD008884_pub2 crossref_primary_10_1016_j_ajem_2019_03_038 crossref_primary_10_1016_j_jcrc_2018_09_031 crossref_primary_10_1002_14651858_CD011573_pub2 crossref_primary_10_1002_14651858_CD004039_pub2 crossref_primary_10_1016_j_jclinepi_2015_08_027 crossref_primary_10_1002_14651858_CD011343_pub2 crossref_primary_10_1007_s11916_024_01298_4 crossref_primary_10_1002_14651858_CD011649_pub2 crossref_primary_10_1016_j_joim_2024_04_003 crossref_primary_10_1002_14651858_CD013121_pub2 crossref_primary_10_1002_14651858_CD001023_pub2 crossref_primary_10_1002_14651858_CD001023_pub3 crossref_primary_10_1186_s12888_016_1173_2 crossref_primary_10_1186_s13063_021_05759_8 crossref_primary_10_1080_08870446_2014_960653 crossref_primary_10_1002_14651858_CD010297_pub2 crossref_primary_10_1002_14651858_CD010297_pub3 crossref_primary_10_1002_14651858_CD011737_pub3 crossref_primary_10_1002_14651858_CD006803_pub4 crossref_primary_10_1002_14651858_CD011737_pub2 crossref_primary_10_1002_14651858_CD015059 crossref_primary_10_1002_14651858_CD015173 crossref_primary_10_1016_j_clnu_2022_11_015 crossref_primary_10_1002_14651858_CD003047_pub3 crossref_primary_10_1016_j_clnu_2021_05_025 crossref_primary_10_1002_14651858_CD006804_pub3 crossref_primary_10_1002_jrsm_1392 crossref_primary_10_1002_14651858_CD012334_pub2 crossref_primary_10_1016_j_jclinepi_2013_09_004 crossref_primary_10_1002_14651858_CD009885_pub3 crossref_primary_10_1002_14651858_CD013086 crossref_primary_10_1111_aas_13072 crossref_primary_10_1002_14651858_CD009885_pub2 crossref_primary_10_1002_14651858_CD013089 crossref_primary_10_1016_j_ajog_2022_04_023 crossref_primary_10_1002_14651858_CD013081 crossref_primary_10_1016_j_jclinepi_2016_07_003 crossref_primary_10_1038_s44221_023_00121_5 crossref_primary_10_3233_WOR_203174 crossref_primary_10_1016_j_jclinepi_2021_07_002 crossref_primary_10_1002_14651858_CD003177_pub5 crossref_primary_10_1002_14651858_CD003177_pub3 crossref_primary_10_1002_14651858_CD003177_pub4 crossref_primary_10_1002_14651858_CD013090 crossref_primary_10_1002_14651858_CD011648_pub2 crossref_primary_10_1002_14651858_CD012814_pub2 crossref_primary_10_1016_j_heliyon_2023_e21927 crossref_primary_10_1002_sim_7491 crossref_primary_10_1093_postmj_qgad130 crossref_primary_10_1002_14651858_CD002102_pub3 crossref_primary_10_1002_14651858_CD009182_pub2 crossref_primary_10_1177_1359105321990810 crossref_primary_10_1159_000444243 crossref_primary_10_1002_14651858_CD014278 crossref_primary_10_1016_j_jclinepi_2014_04_002 crossref_primary_10_1002_14651858_CD010277_pub2 crossref_primary_10_1002_14651858_CD010277_pub3 crossref_primary_10_1038_s41562_024_01940_6 crossref_primary_10_1002_14651858_CD013060 crossref_primary_10_1111_apt_12803 crossref_primary_10_1002_14651858_CD011197_pub3 crossref_primary_10_1002_14651858_CD011197_pub2 crossref_primary_10_1016_j_apmr_2018_12_036 crossref_primary_10_1186_s12874_016_0287_z crossref_primary_10_1002_14651858_CD006575_pub3 crossref_primary_10_1002_14651858_CD013197 crossref_primary_10_1053_j_jvca_2013_01_004 crossref_primary_10_1186_s13643_017_0449_z crossref_primary_10_1016_j_jclinepi_2020_05_009 crossref_primary_10_1016_j_jamda_2015_07_010 crossref_primary_10_1002_14651858_CD010903_pub2 crossref_primary_10_1161_JAHA_119_014890 crossref_primary_10_3389_fpubh_2024_1414070 crossref_primary_10_1002_14651858_CD011561_pub2 crossref_primary_10_1371_journal_pone_0107057 crossref_primary_10_1002_14651858_CD013653_pub2 crossref_primary_10_1002_14651858_CD007469_pub2 crossref_primary_10_1002_14651858_CD014497 crossref_primary_10_1016_j_amepre_2016_06_008 crossref_primary_10_1002_14651858_CD013123_pub2 crossref_primary_10_1002_14651858_CD013289 crossref_primary_10_1371_journal_pone_0074558 crossref_primary_10_1002_14651858_CD006390_pub2 crossref_primary_10_1002_14651858_CD014371 crossref_primary_10_1002_14651858_CD008735_pub3 crossref_primary_10_1002_14651858_CD008735_pub2 crossref_primary_10_1002_14651858_CD011094_pub3 crossref_primary_10_1002_14651858_CD010180_pub2 crossref_primary_10_1002_14651858_CD011094_pub4 crossref_primary_10_1002_14651858_CD015119 crossref_primary_10_1002_14651858_CD006573_pub3 crossref_primary_10_1002_14651858_CD013175 crossref_primary_10_1002_14651858_CD013174 crossref_primary_10_1016_j_ijid_2022_01_002 crossref_primary_10_1002_14651858_CD008717_pub2 crossref_primary_10_1002_14651858_CD008717_pub3 crossref_primary_10_1002_14651858_CD012244_pub2 crossref_primary_10_1111_jebm_12344 crossref_primary_10_1002_14651858_CD013125_pub2 crossref_primary_10_1002_14651858_CD004149_pub3 crossref_primary_10_1080_19439342_2022_2153380 crossref_primary_10_1002_da_22472 crossref_primary_10_3238_arztebl_2017_0635 crossref_primary_10_1002_14651858_CD010162_pub2 crossref_primary_10_1016_j_maturitas_2016_01_012 crossref_primary_10_1016_j_jclinepi_2023_09_001 crossref_primary_10_1111_1471_0528_12914 crossref_primary_10_1002_14651858_CD013203_pub2 crossref_primary_10_1186_s13063_016_1331_3 crossref_primary_10_1002_14651858_CD011769_pub2 crossref_primary_10_1002_14651858_CD011973_pub2 crossref_primary_10_1111_aas_14140 crossref_primary_10_1111_aas_14143 crossref_primary_10_3109_0284186X_2014_954677 crossref_primary_10_1002_14651858_CD011646_pub2 crossref_primary_10_1002_14651858_CD010546_pub2 crossref_primary_10_1016_j_ijnurstu_2014_11_008 crossref_primary_10_1002_14651858_CD009933_pub2 crossref_primary_10_1002_14651858_CD013157 crossref_primary_10_1002_14651858_CD013156 crossref_primary_10_1002_14651858_CD013155 crossref_primary_10_1186_s13643_020_01566_5 crossref_primary_10_1002_14651858_CD002149 crossref_primary_10_1177_00220345211025242 |
ContentType | Journal Article |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 DOA |
DOI | 10.3310/hta16350 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic DOAJ Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 2046-4924 |
ExternalDocumentID | oai_doaj_org_article_0dc2dfabefc24740adfa31fbdf43cb2b 22989478 10_3310_hta16350 |
Genre | Research Support, Non-U.S. Gov't Journal Article Review |
GrantInformation | National Institute for Health Research Health Technology Assessment programme. |
GrantInformation_xml | – fundername: Medical Research Council grantid: G0800800 – fundername: Medical Research Council grantid: G0802413 – fundername: Medical Research Council grantid: G0701659 |
GroupedDBID | --- 53G 5GY AAYXX ADBBV ADDVE AENEX ALMA_UNASSIGNED_HOLDINGS BAWUL BCNDV CITATION CZQ DIK EBS EJD F5P GROUPED_DOAJ OK1 P2P P6G TR2 W2D CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c383t-4d766163ab8ed6497e91f8b81909c65a9b6bfd98a8aa3f80fc2f1305756436f23 |
IEDL.DBID | DOA |
ISSN | 1366-5278 2046-4924 |
IngestDate | Wed Aug 27 01:29:38 EDT 2025 Fri Jul 11 06:43:05 EDT 2025 Sat May 31 02:14:04 EDT 2025 Tue Jul 01 01:47:54 EDT 2025 Thu Apr 24 23:12:24 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 35 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c383t-4d766163ab8ed6497e91f8b81909c65a9b6bfd98a8aa3f80fc2f1305756436f23 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
OpenAccessLink | https://doaj.org/article/0dc2dfabefc24740adfa31fbdf43cb2b |
PMID | 22989478 |
PQID | 1041325827 |
PQPubID | 23479 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_0dc2dfabefc24740adfa31fbdf43cb2b proquest_miscellaneous_1041325827 pubmed_primary_22989478 crossref_primary_10_3310_hta16350 crossref_citationtrail_10_3310_hta16350 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2012-09-01 |
PublicationDateYYYYMMDD | 2012-09-01 |
PublicationDate_xml | – month: 09 year: 2012 text: 2012-09-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Health technology assessment (Winchester, England) |
PublicationTitleAlternate | Health Technol Assess |
PublicationYear | 2012 |
Publisher | NIHR Journals Library |
Publisher_xml | – name: NIHR Journals Library |
SSID | ssj0041651 |
Score | 2.5563493 |
SecondaryResourceType | review_article |
Snippet | The design of randomised controlled trials (RCTs) should incorporate characteristics (such as concealment of randomised allocation and blinding of participants... Background: The design of randomised controlled trials (RCTs) should incorporate characteristics (such as concealment of randomised allocation and blinding of... |
SourceID | doaj proquest pubmed crossref |
SourceType | Open Website Aggregation Database Index Database Enrichment Source |
StartPage | 1 |
SubjectTerms | allocation concealment Bias blinding Data Interpretation, Statistical Databases, Bibliographic Epidemiologic Research Design Humans meta-analysis Meta-Analysis as Topic meta-epidemiological study Outcome Assessment, Health Care - methods Outcome Assessment, Health Care - standards Outcome Assessment, Health Care - statistics & numerical data randomisation Randomized Controlled Trials as Topic - standards Randomized Controlled Trials as Topic - statistics & numerical data Reproducibility of Results |
Title | Influence of reported study design characteristics on intervention effect estimates from randomised controlled trials: combined analysis of meta-epidemiological studies |
URI | https://www.ncbi.nlm.nih.gov/pubmed/22989478 https://www.proquest.com/docview/1041325827 https://doaj.org/article/0dc2dfabefc24740adfa31fbdf43cb2b |
Volume | 16 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LS8QwEA7qQbyIb9cXEQRPxd2km6beVBQVFAQF8VImTYKC24rW_-TPdCZp1xUUL95KmjYhM81808x8w9ie0uBk30Fi00wmdLKUgDcmER5tX2ly6APlO19dq_O79PJ-eD9R6otiwiI9cFy4g74thfVgnC9FmqX4qAc58Mb6VJZGGNp90eZ1zlTcgxFlDNuMK4WuVqYj7axELHPw2ABiEMqznzBEga__d5AZjM3ZAptvUSI_irNbZFOuWmKzV-05-DL7uOhqi_Da8_jf31keuGK5DUEZvPxOxczrij9NBDjyGMnBiWVjRICTU6YJR9Nla5Q9vq2NYn_Gy1Db4-0Qm0boSWMDtFwmNPzINZC4r0qzJPYwFXTCV9jd2entyXnS1lxISvRVmyS1GVpsJcFoZ1WaZy4feG0IN-SlGkJulPE216ABpNd9lIpHM4igD6GN8kKuspmqrtw6ZYNLrayWGj_51EirrQU78EIbA0473WP7nQCKsiUkp7oYzwU6JiSqohNVj-2Oe75EEo4f-hyTDMf3iTY7NKAyFa0yFX8pEw7UaUCBS01nJ1C5-v0Nh0NrL4ZaZD22FlVjPJQILPaZ3viPKWyyOcRkIoaxbbGZ5vXdbSPuacwOmz55uNkJiv4JejwKWA |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Influence+of+reported+study+design+characteristics+on+intervention+effect+estimates+from+randomised+controlled+trials%3A+combined+analysis+of+meta-epidemiological+studies&rft.jtitle=Health+technology+assessment+%28Winchester%2C+England%29&rft.au=J+Savovi%C4%87&rft.au=HE+Jones&rft.au=DG+Altman&rft.au=RJ+Harris&rft.date=2012-09-01&rft.pub=NIHR+Journals+Library&rft.issn=1366-5278&rft.eissn=2046-4924&rft.volume=16&rft.issue=35&rft_id=info:doi/10.3310%2Fhta16350&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_0dc2dfabefc24740adfa31fbdf43cb2b |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1366-5278&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1366-5278&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1366-5278&client=summon |